John H. Van Drie is a multi-faceted, innovative, 20-year veteran of drug discovery, experienced as an entrepreneur, scientist and an executive. He has exceptional expertise in introducing novel approaches and advanced technology into drug discovery/development. He is a passionate drug-hunter who has contributed to the teams which discovered three marketed drugs. He is an articulate, persuasive bridge-builder excelling in helping to build new organizations in the wake of mergers. He is an internationally-recognized leader in Computer-Aided Drug Discovery (CADD), and a pioneer in of virtual screening.

Prior to launching Van Drie Research in 2007, he held posts at:

  • The Novartis Institutes for BioMedical Research, Cambridge, MA
  • Vertex Pharmaceuticals, Cambridge, MA
  • Pharmacia, Kalamazoo, MI

John was also a founding member of BioCAD (a Silicon Valley startup acquired by Accelrys, which still markets BioCAD's Catalyst software).

John is an internationally-recognized expert in the area of computer-aided drug design (CADD), and was the Chair of the first Gordon Conference on CADD. He is one of the pioneers of virtual screening, and pharmacophore-based methods.

He studied theoretical chemistry as an NSF Fellow with W. A. Goddard III at Caltech; his PhD thesis, "Information Theory and Quantum Mechanics", was the first-ever exploration of that topic. He also studied with I. Prigogine as a BAEF Fellow at the Univ. Libre de Bruxelles.

John has been active in drug discovery since the mid-1980's. Here are his publications in the biomedical arena that have been indexed in PubMed.

Here he is on LinkedIn.

spacer Richard Feynman
"Science is a way to teach how something gets to be known, what is not known, to what extent things are known (for nothing is known absolutely), how to handle doubts and uncertainty, what the rules of evidence are, how to think about things so that judgments can be made, how to distinguish truth from fraud, and from show."
—Richard Feynman

Designed by www.KathyCrowe.com